KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 0.75.

  • Recursion Pharmaceuticals' Equity Ratio rose 360.6% to 0.75 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75, marking a year-over-year increase of 360.6%. This contributed to the annual value of 0.71 for FY2024, which is 76.02% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Equity Ratio stood at 0.75 for Q3 2025, which was up 360.6% from 0.71 recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Equity Ratio registered a high of 0.92 during Q2 2021, and its lowest value of 0.86 during Q1 2021.
  • For the 5-year period, Recursion Pharmaceuticals' Equity Ratio averaged around 0.65, with its median value being 0.71 (2023).
  • In the last 5 years, Recursion Pharmaceuticals' Equity Ratio surged by 22875.58% in 2021 and then plummeted by 3023.69% in 2022.
  • Recursion Pharmaceuticals' Equity Ratio (Quarter) stood at 0.89 in 2021, then decreased by 22.13% to 0.69 in 2022, then grew by 2.34% to 0.71 in 2023, then increased by 0.76% to 0.71 in 2024, then grew by 4.72% to 0.75 in 2025.
  • Its Equity Ratio stands at 0.75 for Q3 2025, versus 0.71 for Q2 2025 and 0.72 for Q1 2025.